ABBOTINDIA · NSE
Abbott India Limited
₹27,270
+5.25% (+₹1,360)
Prev. close
₹25,910
Volume
38,339
Delivery %
66.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kartik Rajendran
Headquarters
Mumbai
Employees
3,679
Website
abbott.co.inExchange
View on NSE ↗Key stats
Market cap
₹57,946.85 Cr
P/E ratio (TTM)
35.9
Dividend yield
2.03%
EPS (TTM)
₹759.16
Beta (1Y · daily vs NIFTY 50)
0.27
Beta (5Y · monthly vs NIFTY 50)
0.15
Shares float
51.93 L
EPS · quarter ended Jun 2026
₹201.66
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,310.02 Cr | ₹4,919.27 Cr | ₹5,346.73 Cr | ₹5,847.19 Cr | ₹6,406.97 Cr | ₹6,926.90 Cr | |
| EBITDA | ₹1,002.36 Cr | ₹1,164.93 Cr | ₹1,359.78 Cr | ₹1,701.37 Cr | ₹1,970.18 Cr | ₹2,180.22 Cr |
| ₹690.69 Cr | ₹798.70 Cr | ₹949.41 Cr | ₹1,201.22 Cr | ₹1,414.44 Cr | ₹1,552.02 Cr | |
| Diluted EPS | ₹325.04 | ₹375.86 | ₹446.78 | ₹565.28 | ₹665.62 | ₹730.36 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,840.45 Cr | ₹4,224.12 Cr | ₹4,555.51 Cr | ₹5,193.49 Cr | ₹5,917.31 Cr | ₹6,501.93 Cr | |
| Total debt | ₹152.58 Cr | ₹151.69 Cr | ₹113.17 Cr | ₹83.23 Cr | ₹196.67 Cr | ₹171.99 Cr |
| Stockholders' equity | ₹2,602.16 Cr | ₹2,819.79 Cr | ₹3,188.54 Cr | ₹3,698.89 Cr | ₹4,233.15 Cr | ₹4,774.19 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹893.39 Cr | ₹1,212.81 Cr | ₹1,011.84 Cr | ₹1,319.24 Cr | |
| Investing cash flow | — | — | ₹-147.71 Cr | ₹-416.03 Cr | ₹182.18 Cr | ₹-371.38 Cr |
| — | — | ₹-638.72 Cr | ₹-744.71 Cr | ₹-925.17 Cr | ₹-1,066.12 Cr | |
| Capital expenditure | — | — | ₹-34.11 Cr | ₹-48.33 Cr | ₹-52.60 Cr | ₹-40.92 Cr |
| End cash position | — | — | ₹239.67 Cr | ₹291.74 Cr | ₹560.59 Cr | ₹442.33 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Abbott India Limited | ₹55,513.80 Cr | ₹25,910 | 34.4 | 11.63 | 32.5% | 0.04 | +8.1% | -16.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
35 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Abbott India stock rallies as investors respond to strong recent earnings
Abbott India stock rallied over 5% on September 18, 2026, reaching an intraday high of INR 27,490. Investors responded to strong recent earnings, with the company reporting high single-digit revenue growth and double-digit net profit expansion in its latest quarter. The stock outperformed its sector peers, supported by positive technical indicators.
Abbott India Q2 Results FY27: Date and Expectations
Abbott India's Q2 FY27 results date remains unconfirmed as of September 8, 2026, with the company yet to file a board meeting intimation. Indian regulations require results to be published by November 14, 2026. The upcoming results will be compared against Q2 FY26, which reported a profit of Rs 415.00 crore.